The following is an interview with Dr Toni K. Choueiri, medical oncologist at the Dana-Farber Cancer Institute, Boston, US, about the kidney cancer highlights from the European Society of Medical Oncology (ESMO) 2017 conference in Madrid, Spain this week. During this interview he talks about the updated CABOSUN (cabozantinib versus sunitinib) clinical trial results, updated CheckMate-214 (nivolumab plus ipilimuab versus sunitinib) results, and the role of cytoreductive nephrectomy in patients with advanced kidney cancer (SURTIME and CARMENA trials).
Kidney cancer highlights from the European Society of Medical Oncology
14 Sep 2017
Cabometyx
cabozantinib
checkpoint inhibitors
cytoreductive nephrectomy
immunotherapy
ipilimumab
Keytruda
nivolumab
Opdivo
renal cell carcinoma
TKIs
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab COVID-19 pembrolizumab cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers targeted therapy papillary RCC everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec